Plavix Patent Protected by Supreme Court Denial

The Supreme Court denial of Apotex’s petition challenging a patent on Sanofi-Aventis and Bristol-Myers Squibb’s blood-thinner drug Plavix protects a patent on the drug that Apotex had contended was not strong enough to maintain validity. The court’s decision not to review the case ends an eight-year legal battle over the blockbuster drug that began when Apotex applied for FDA approval to market a generic Plavix (clopidogrel bisulfate) in November 2001.
Washington Drug Letter